A great comprehensive slid show and narration. For those that are long such as myself this meeting will reassures your investment in Accuray going forward.
Polygon Management Ltd. just filed a portfolio update (also known as a 13-F), dated May 13, 2016. The portfolio holdings are as of March 31, 2016.
Polygon Management Ltd. reported adding to its positions of:
Wright Medical Group
The Spectranetics Corporation
Jazz Pharmaceuticals plc
General Electric Capital Corporation
Cobalt International Energy
Arris Group Inc
AmTrust Financial Services
Wonder why this wasn't posted on Arrays website, good post hemmerjohn9, thanks
ARAY is rated BUY, based on the average of 9 Wall Street analyst ratings. Among these analysts, 55.6% (5) of them have positive ratings on the stock. 11.1% (1) of them have negative ratings. 33.3% (3) of them have neutral ratings. Analysts have an average $8.78 Target Price on ARAY, implying 61.1% Upside to its current price of $5.45.
It's inevitable that the CEO Josh Levine will sell Accuray, that's his history when he takes over a company but in the interim this is what we have. I would like to see just once a quarter with no short falls...just once, ok consistently
Accuray Signs Long-Term Strategic Development and Supply Agreement with medPhoton for Volumetric Image Guidance Solutions for the CyberKnife® System
Collaboration Designed to Expand Clinical Versatility of the CyberKnife® System with Addition of medPhoton Novel Imaging Solution
PR Newswire Accuray Incorporated
12 hours ago
SUNNYVALE, Calif., May 1, 2016 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today that the company has signed an agreement with medPhoton GmbH to collaborate on integration of its ImagingRing® system, a new technology for volumetric image guidance, with the CyberKnife® System. The ImagingRing provides a range of advanced imaging capabilities including large field-of-view cone beam CT. This long-term strategic agreement will provide Accuray with certain exclusive development, sales and distribution rights of the unique ImagingRing for use in adaptive radiation therapy, SBRT and robotic radiosurgery.
Accuray beats 3Q profit forecasts
Accuray posts 3Q profit of $756,000, result tops expectations
SUNNYVALE, Calif. (AP) _ Accuray Inc. (ARAY) on Tuesday reported fiscal third-quarter net income of $756,000, after reporting a loss in the same period a year earlier.
On a per-share basis, the Sunnyvale, California-based company said it had profit of 1 cent.
The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 5 cents per share.
The radiation oncology company posted revenue of $105.3 million in the period.
Accuray expects full-year revenue in the range of $395 million to $405 million.
NASDAQ4:00 PM EDT
Accuray beats 3Q profit forecasts AP 10 mins ago
Accuray Inc Earnings Call scheduled for 4:30 pm ET today CCBN 46 mins ago
Accuray shares have decreased 16 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $5.69, a decrease of 37 percent in the last 12 months.
Accuray Hosts Regional AERO Users' Meeting
Leading Oncology Specialists Discuss Best Practices and Innovations in Cancer Treatment
PR Newswire Accuray Incorporated
8 hours ago
SUNNYVALE, Calif., April 22, 2016 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today that the Accuray Exchange in Radiation Oncology (AERO™) Users' Meeting was held April 10 – 11, 2016 at the Palace Hotel in San Francisco, California. The two day summit, coordinated in partnership with teams from several University of California campuses, brought together radiation oncologists, physicists, therapists and administrators from around the world to discuss best practices and the future of radiation oncology. Founded in 2011, AERO was created for CyberKnife® System and TomoTherapy® System users dedicated to advancing patient care through worldwide clinical and technical collaboration.
Research shows 98% cure rate for prostate cancer using Stereotactic Body Radiation Therapy
Apr 18, 2016
DALLAS – April 18, 2016 – A five-year study shows that Stereotactic Body Radiation Therapy (SBRT) to treat prostate cancer offers a higher cure rate than more traditional approaches, according to researchers at UT Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center.
The study – the first trial to publish five-year results from SBRT treatment for prostate cancer – found a 98.6 percent cure rate with SBRT, a noninvasive form of radiation treatment that involves high-dose radiation beams entering the body through various angles and intersecting at the desired target. It is a state-of-the-art technology that allows for a concentrated dose to reach the tumor while limiting the radiation dose to surrounding healthy tissue.
Dr. Raquibul Hannan
Dr. Raquibul Hannan
“The high cure rate is striking when compared to the reported five-year cure rates from other approaches like surgery or conventional radiation, which range between 80 to 90 percent, while the side effects of this treatment are comparable to other types of treatment,” said Dr. Raquibul Hannan, Assistant Professor of Radiation Oncology and lead author for the study. “What we now have is a more potent and effective form of completely noninvasive treatment for prostate cancer, conveniently completed in five treatments.”
IMO they will beat 3 quarter year ago and perhaps more, great buys alebiglio
Very good presentation, very up to date all except s/p
Accuray would make a nice fit into GE's health care product line.
Does GE have and an oncology business or unit?
Accuray and GE Capital Healthcare Equipment Finance Announce Healthcare Financing Collaboration Agreement
PR Newswire Accuray Europe
8 hours ago
PARIS and LONDON, February 25, 2016 /PRNewswire/ --
New Agreement Provides Healthcare Professionals with Streamlined, Cost-Effective Options for Accessing the CyberKnife® and TomoTherapy® Systems
Accuray Europe and GE Capital Healthcare Equipment Finance announced today they have signed a collaboration agreement to develop sustainable financing options that will increase market access to the CyberKnife® and TomoTherapy® Systems. These innovative solutions provide excellent treatment outcomes for a wide range of cancerous and non-cancerous tumors. The new financing program will make it even easier for clinicians throughout Europe to offer their patients a non-invasive treatment option that delivers precise radiation therapy while maximizing patients' quality of life during and after treatment.